Core Viewpoint - Nanjing Weilizhibo Biotechnology Co., Ltd. officially listed on the Hong Kong Stock Exchange on July 25, 2025, with an IPO price of HKD 35 per share, aiming to raise approximately USD 189 million for clinical development and operational enhancements [1][2]. Company Overview - Founded in 2012, Weilizhibo is a clinical-stage biotechnology company focused on discovering, developing, and commercializing new therapies for cancer, autoimmune diseases, and other major diseases [2]. - The company has a diverse product portfolio with 14 innovative candidates, including 4 core products, all of which are leading in global clinical progress within their respective categories [2]. Business Model and Technology Platforms - Weilizhibo's core business model emphasizes self-discovery, development, and commercialization of tumor immunotherapies, focusing on three main areas: IO 2.0, T-cell engagers (TCE), and antibody-drug conjugates (ADC) [2][4]. - The company has developed proprietary technology platforms, including LeadsBody™ and X-body™, which support the development of bispecific antibodies and enhance therapeutic efficacy while minimizing systemic toxicity [4]. Clinical Pipeline and Research Highlights - The company has established a robust pipeline with 12 products targeting tumors, including 3 monoclonal antibodies, 5 bispecific antibodies, and 3 ADCs [2][4]. - LBL-024, a bispecific antibody targeting PD-L1 and 4-1BB, has shown promising results in clinical trials for treating advanced pulmonary neuroendocrine carcinoma, achieving an objective response rate (ORR) of 75% and a disease control rate (DCR) of 92.3% [7][8]. - LBL-024 is the first targeted therapy for the 4-1BB receptor in the registration clinical stage, with potential applications across various cancers, including small cell lung cancer and ovarian cancer [8][10]. Funding Utilization - The proceeds from the IPO will be allocated as follows: approximately 65% for clinical development and regulatory affairs, 15% for enhancing preclinical assets and expanding the pipeline, 10% for capacity enhancement and commercialization, and 10% for working capital and general corporate purposes [1].
维立志博正式于港交所上市！ 募资1.89亿美元